The 36th annual JP Morgan Healthcare Conference is being held in San Francisco, CA from January 8-11, 2018. Surprises are not uncommon at JP Morgan and companies do not typically preannounce what they will be presenting, but our analysts have selected a number of companies to watch throughout the week to prime you for the jam-packed meeting. Here we summarize the current affairs surrounding these companies and potential discussion points to be presented. We have also included a graph of drug companies presenting at JP Morgan with the greatest number of large impact catalysts expected in 2018 in each market cap grouping, one metric of interest.

Stay tuned for Biomedtracker’s full real-time coverage of the 2018 JP Morgan Healthcare Conference. Our daily reports published each evening will bring you the important pipeline updates and key takeaways from the entire day’s presentations. With Biomedtracker helping you navigate along the way, you’ll stay informed on the latest updates in drug development and not miss a beat from the biggest investor healthcare conference of the year.

Companies highlighted in this preview:

• Alexion (ALXN)
• Alkermes (ALKS)
• Allergan (AGN)
• Alnylam (ALNY)
• Amicus (FOLD)
• Array (ARRY)
• Ascendis (ASND)
• Audentes (BOLD)
• Biogen (BIIB)
• Bristol-Myers Squibb (BMY)
• Celgene (CELG)
• Cellectis (CLLS)
• Clovis (CLVS)
• Dova (DOVA)
• Gilead (GILD)
• Incyte (INCY)
• Ionis (IONS)
• Jazz (JAZZ)
• Juno (JUNO)
• The Medicines Company (MDCO)
• Merck (MRK)
• Nektar (NKTR)
• Regeneron (REGN)
• Roche (RHHBF)
• Sarepta (SRPT)
• Takeda (TKPYY)
• Ultragenyx (RARE)
• Vertex (VRTX)

For the full report, please download the PDF version at the top of this page.

For our disclosures, please read the Biomedtracker Research Standards.